Riassunto: BeOne presenta dati fondamentali di Fase 3 di pazienti affetti da CLL di età superiore agli 80 anni in occasione di EHA 2026, ribadendo il vantaggio di BRUKINSA

Key Takeaway: BeOne presented Phase 3 data on patients over 80 years old with CLL at EHA 2026, emphasizing the benefits of BRUKINSA. The findings contribute to understanding treatment options for elderly patients with chronic lymphocytic leukemia. Further details about the study's outcomes and implications were not disclosed.